Small molecule · Inhibitor of cytidine deaminase (CDA) · developed by Taiho Pharmaceutical Co.
Cedazuridine is a cytidine deaminase inhibitor that binds and inhibits the enzyme CDA, which degrades cytidine analogs in the gastrointestinal tract and liver. Given with decitabine, it increases systemic decitabine exposure. It is combined with decitabine in INQOVI for myelodysplastic syndromes and acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06445959 | Phase 1/2 | Mutant IDH1 Inhibitor Olutasidenib | Recruiting | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mutant IDH1 Inhibitor Olutasidenib
Updated Nov 1, 2026.